Dato-DXd: a new ADC on the block Published 2021-05-17 Download video MP4 360p Recommendations 11:00 Integration by parts with u-sub. Where’s the mistake? Integral of sin(ln(2x)). Reddit r/calculus 01:52 Side Effects of Oxaliplatin 03:41 ASCO GU 2024 highlights: BRCAAway, CONTACT-2 and KEYNOTE-564 03:22 PTEN protein and gene expression as a biomarker in breast cancer 05:45 HER2-Positive Breast Cancer: A Paradigm Shift in Diagnosis and Therapy 01:41 Current and emerging applications for ctDNA analysis in prostate cancer 01:48 MOVES: assessing the value of exercise in enhancing cancer prognoses 02:06 Variability in genomic testing among prostate cancer care providers 01:26 Management of urothelial carcinoma with positive pelvic/retroperitoneal lymph nodes 02:44 The role of radiation in managing high-risk localized prostate cancer 03:47 Salvage radiotherapy in biochemically recurrent prostate cancer 01:09 What role does FDG-PET have in managing bladder cancer? Similar videos 27:03 Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference 56:23 Are You Prepared for the New Wave of ADCs in NSCLC? Targeting HER2, HER3, TROP2, and Others 51:40 TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal 01:37 TROPION-Lung01 & TROPION-Lung05: datopotamab deruxtecan for NSCLC 02:07 Emerging toxicities associated with ADCs 01:42 What are Antibody Drug Conjugates (ADCs) 59:55 Under Pressure to Improve: Unlocking the Power of ADCs to Transform the Treatment of Lung Cancer 49:56 Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations 58:27 Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies 01:06 PSMA ADC in prostate cancer: Phase I results 00:50 PSMA ADC for prostate cancer 08:53 Interim results from DESTINY-Lung01: T-DXd in HER2-overexpressing NSCLC 07:12 Brief introduction of antibody drug conjugates BOC Sciences 56:32 Antibody Drug Conjugates for Cancer 24:23 Dr. Hope Rugo: ADC's Current Clinical Evidence 45:09 Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC to Address Unmet Needs 02:10 Daiichi Sankyo in Oncology EN 01:45 Strategies to Target HER2 in Lung Cancer More results